The CAPN1 antibody is a crucial tool for studying calpain-1. a calcium-dependent cysteine protease encoded by the *CAPN1* gene. Calpain-1. part of the calpain family, regulates diverse cellular processes, including signal transduction, apoptosis, cytoskeletal remodeling, and cell migration. It exists as a heterodimer, comprising an 80 kDa catalytic subunit (regulated by calcium) and a 30 kDa regulatory subunit (encoded by *CAPNS1*). Dysregulation of calpain-1 is implicated in neurodegenerative diseases (e.g., Alzheimer’s), muscular dystrophy, and cancer, making CAPN1 antibodies vital for both research and diagnostic applications.
CAPN1 antibodies are typically developed using immunogens from specific regions of the calpain-1 protein, such as the catalytic domain or regulatory segments. These antibodies enable detection of calpain-1 expression and localization via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Their specificity is often validated using knockout cell lines or tissues to confirm minimal cross-reactivity with other calpain isoforms (e.g., calpain-2).
Polyclonal CAPN1 antibodies recognize multiple epitopes, offering high sensitivity but potential cross-reactivity, whereas monoclonal antibodies provide consistent specificity. Researchers prioritize antibodies validated for particular applications to ensure reliability. CAPN1 antibodies also aid in studying calpain activation mechanisms, substrate cleavage, and therapeutic targeting in disease models. Their role in elucidating calcium-mediated proteolytic pathways underscores their importance in cell biology and translational research.